PharmaRoth Labs Inc (ROTH) Stock Analysis
Verdict: AVOID
Terminal insolvency risk and multi-year reporting silence make this a 'zombie' stock with high probability of total capital loss.
Investment score: 1/100
Analysis as of
Is PharmaRoth Labs Inc stock worth reviewing? The TradeMates thesis
The model identifies PharmaRoth Labs as a high-risk micro-cap in a state of terminal decline. Financial data is dangerously stale, and the balance sheet shows deep insolvency.
7-factor investment score
- Valuation: 0/100 (weight 20%)
- Financial Health: 0/100 (weight 15%)
- Technical Momentum: 5/100 (weight 15%)
- Earnings Quality: 0/100 (weight 15%)
- Insider Sentiment: 0/100 (weight 10%)
- Analyst Consensus: 0/100 (weight 10%)
- Risk-Adjusted Return: 0/100 (weight 15%)
PharmaRoth Labs Inc opportunities and risks
What speaks for ROTH
- Speculative Reverse Merger Proxy
What speaks against ROTH
- Terminal Insolvency
Frequently asked questions about PharmaRoth Labs Inc (ROTH)
Is ROTH stock a good investment?
The TradeMates model rates PharmaRoth Labs Inc as AVOID with an investment score of 1/100. The model identifies PharmaRoth Labs as a high-risk micro-cap in a state of terminal decline. Financial data is dangerously stale, and the balance sheet shows deep insolvency. This is algorithmic model output, not personal investment advice.
Is ROTH stock a buy?
The TradeMates model verdict for ROTH is AVOID with an investment score of 1/100. Treat this as a model signal to review, not a personal buy recommendation.